Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: Oral administration of DNA alginate nanovaccine induced immune-protection against Helicobacter pylori in Balb/C mice

Fig. 2

(A) Transcription of the recombinant vaccine at mRNA level. L1: Negative control; L2 and L3: Alginate/pCI-neo-UreH; L4 and L5: pCI-neo-UreH; M: 100 bp DNA marker. (B) Expression of recombinant Alginate/pCI-neo-UreH in protein level. L1: Negative control; L2: Alginate/pCI-neo; L3: Alginate/pCI-neo-UreH; L4: pCI-neo-UreH; M: protein marker. (C) Bacterial burdens in the stomach tissues of BALB/c mice 5 days’ post-challenge. The stars (*) are according to the PBS group. IgG (D), IFN-γ (E) and IL-17 A(F) levels were found in the splenocyte supernatants of the control and immunized groups. PBS was used as a control. * p < 0.05, ** p < 0.01, *** p < 0.001

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us